Please login to the form below

Not currently logged in
Email:
Password:

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

Takeda

Takeda, Japan’s largest pharmaceutical company by sales, has announced that it’s considering a possible takeover deal for Shire, a biopharma focused on rare diseases.

The news sparked a 25% surge in Shire’s shares during yesterday morning’s trading however according to Takeda, the consideration of such an offer is at a ‘preliminary’ and exploratory’ stage, with no actual approach made to the board of Shire.

In a press release announced earlier today, Takeda said a “potential transaction with Shire presents an opportunity to strengthen the company’s core therapeutic areas of oncology, gastrointestinal and neuroscience”.

It also added that the deal could build on Takeda’s “current strong momentum”, and could create a “truly global, value-based Japanese biopharmaceutical leader”.

Takeda, which has until 25 April to make a formal offer, isn’t the only company that has seen potential with Shire, as it was recently tipped as the next big pharma takeover after AbbVie’s failed takeover bid in 2014.

That particular deal, which saw AbbVie offer $55bn for the biopharma, came to a halt after the US introduced new measures to discourage tax inversion deals.

Article by
Gemma Jones

29th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics